Tumor growth of PC9 xenografts with low-dose EGFR TKI + BEV therapy. Mice bearing PC9 xenografts were treated 10 mg/kg of gefitinib or gefitinib (10 mg/kg) + BEV (5 mg/kg), n=4-5. Data are presented as the mean ± SD from week 0 (baseline) to week 2. *p < 0.05
Tumor Volume (mm$^3$)

- PC9-Ctrl
- PC9-gefitinib
- PC9-gefitinib+BEV

Baseline | Week 1 | Week 2
---|---|---

* *